The premier episode of Zoom in on Dementia & Alzheimer's focused on Leqembi, a new anti-amyloid treatment for Alzheimer's disease that received conditional approval from the FDA in January 2023.
Dr. Sharon Cohen, neurologist and medical director at Toronto Memory Program, and host Nancy Lynn discussed the drug's benefits, availability, potential side effects, cost, and more, as well as other drugs in development for Alzheimer's.
Learn more: BrightFocus.org/ADZoom.
For information and free dementia and Alzheimer's disease resources, call BrightFocus Foundation at 1-800-437-2423 to speak with one of our staff members.
#dementia #alzheimers #alzheimer #alzheimersdisease #leqembi #alzheimersawareness
Негізгі бет The New Alzheimer’s Drug: What is Leqembi?
No video
Пікірлер: 14